PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Arterial thromboembolism in cancer patients treated with cisplatin: a systematic review and meta-analysis.

Abstract Cisplatin has been associated with an increased risk of arterial thromboembolic events (ATEs). However, because this association is mostly based on case reports and retrospective studies, we conducted a systemic review and meta-analysis of randomized controlled trials evaluating the incidence and risk of ATEs associated with cisplatin. Eligible studies included prospective randomized phase II and III trials evaluating cisplatin-based vs non-cisplatin-based chemotherapy in patients with solid tumors, which were identified from PubMed articles published between 1990 and 2010. Incidence rates, relative risks (RRs), and 95% confidence intervals (CIs) were calculated using a random effects model. A total of 8216 patients from 38 trials were included. Among patients treated with cisplatin-based chemotherapy, the summary incidence of ATEs was 0.67% (95% CI = 0.40% to 0.95%), and the RR of ATEs was 1.36 (95% CI = 0.86 to 2.17; P = .19). No increase in ATEs was detected in any prespecified subgroup.
PMID
Related Publications

Incidence and risk of treatment-related mortality in cancer patients treated with EGFR-TKIs: a meta-analysis of 22 phase III randomized controlled trials.

Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials.

Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials.

Risk of venous and arterial thromboembolic events in cancer patients treated with gemcitabine: a systematic review and meta-analysis.

Risk of venous thromboembolism in patients with cancer treated with Cisplatin: a systematic review and meta-analysis.

Authors

Mayor MeshTerms
Keywords
Journal Title journal of the national cancer institute
Publication Year Start
%A Proverbs-Singh, Tracy; Chiu, Sophia K.; Liu, Ziyue; Seng, Sonia; Sonpavde, Guru; Choueiri, Toni K.; Tsao, Che-Kai; Yu, Menggang; Hahn, Noah M.; Oh, William K.; Galsky, Matthew D.
%T Arterial thromboembolism in cancer patients treated with cisplatin: a systematic review and meta-analysis.
%J Journal of the National Cancer Institute, vol. 104, no. 23, pp. 1837-1840
%D 12/2012
%V 104
%N 23
%M eng
%B Cisplatin has been associated with an increased risk of arterial thromboembolic events (ATEs). However, because this association is mostly based on case reports and retrospective studies, we conducted a systemic review and meta-analysis of randomized controlled trials evaluating the incidence and risk of ATEs associated with cisplatin. Eligible studies included prospective randomized phase II and III trials evaluating cisplatin-based vs non-cisplatin-based chemotherapy in patients with solid tumors, which were identified from PubMed articles published between 1990 and 2010. Incidence rates, relative risks (RRs), and 95% confidence intervals (CIs) were calculated using a random effects model. A total of 8216 patients from 38 trials were included. Among patients treated with cisplatin-based chemotherapy, the summary incidence of ATEs was 0.67% (95% CI = 0.40% to 0.95%), and the RR of ATEs was 1.36 (95% CI = 0.86 to 2.17; P = .19). No increase in ATEs was detected in any prespecified subgroup.
%K Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Arteries, Cisplatin, Clinical Trials, Phase II as Topic, Clinical Trials, Phase III as Topic, Humans, Incidence, Neoplasms, Randomized Controlled Trials as Topic, Risk, Thromboembolism
%P 1837
%L 1840
%Y 10.1093/jnci/djs435
%W PHY
%G AUTHOR
%R 2012......104.1837P

@Article{Proverbs-Singh2012,
author="Proverbs-Singh, Tracy
and Chiu, Sophia K.
and Liu, Ziyue
and Seng, Sonia
and Sonpavde, Guru
and Choueiri, Toni K.
and Tsao, Che-Kai
and Yu, Menggang
and Hahn, Noah M.
and Oh, William K.
and Galsky, Matthew D.",
title="Arterial thromboembolism in cancer patients treated with cisplatin: a systematic review and meta-analysis.",
journal="Journal of the National Cancer Institute",
year="2012",
month="Dec",
day="05",
volume="104",
number="23",
pages="1837--1840",
keywords="Antineoplastic Agents",
keywords="Antineoplastic Combined Chemotherapy Protocols",
keywords="Arteries",
keywords="Cisplatin",
keywords="Clinical Trials, Phase II as Topic",
keywords="Clinical Trials, Phase III as Topic",
keywords="Humans",
keywords="Incidence",
keywords="Neoplasms",
keywords="Randomized Controlled Trials as Topic",
keywords="Risk",
keywords="Thromboembolism",
abstract="Cisplatin has been associated with an increased risk of arterial thromboembolic events (ATEs). However, because this association is mostly based on case reports and retrospective studies, we conducted a systemic review and meta-analysis of randomized controlled trials evaluating the incidence and risk of ATEs associated with cisplatin. Eligible studies included prospective randomized phase II and III trials evaluating cisplatin-based vs non-cisplatin-based chemotherapy in patients with solid tumors, which were identified from PubMed articles published between 1990 and 2010. Incidence rates, relative risks (RRs), and 95\% confidence intervals (CIs) were calculated using a random effects model. A total of 8216 patients from 38 trials were included. Among patients treated with cisplatin-based chemotherapy, the summary incidence of ATEs was 0.67\% (95\% CI = 0.40\% to 0.95\%), and the RR of ATEs was 1.36 (95\% CI = 0.86 to 2.17; P = .19). No increase in ATEs was detected in any prespecified subgroup.",
issn="1460-2105",
doi="10.1093/jnci/djs435",
url="http://www.ncbi.nlm.nih.gov/pubmed/23093559",
language="eng"
}

%0 Journal Article
%T Arterial thromboembolism in cancer patients treated with cisplatin: a systematic review and meta-analysis.
%A Proverbs-Singh, Tracy
%A Chiu, Sophia K.
%A Liu, Ziyue
%A Seng, Sonia
%A Sonpavde, Guru
%A Choueiri, Toni K.
%A Tsao, Che-Kai
%A Yu, Menggang
%A Hahn, Noah M.
%A Oh, William K.
%A Galsky, Matthew D.
%J Journal of the National Cancer Institute
%D 2012
%8 Dec 05
%V 104
%N 23
%@ 1460-2105
%G eng
%F Proverbs-Singh2012
%X Cisplatin has been associated with an increased risk of arterial thromboembolic events (ATEs). However, because this association is mostly based on case reports and retrospective studies, we conducted a systemic review and meta-analysis of randomized controlled trials evaluating the incidence and risk of ATEs associated with cisplatin. Eligible studies included prospective randomized phase II and III trials evaluating cisplatin-based vs non-cisplatin-based chemotherapy in patients with solid tumors, which were identified from PubMed articles published between 1990 and 2010. Incidence rates, relative risks (RRs), and 95% confidence intervals (CIs) were calculated using a random effects model. A total of 8216 patients from 38 trials were included. Among patients treated with cisplatin-based chemotherapy, the summary incidence of ATEs was 0.67% (95% CI = 0.40% to 0.95%), and the RR of ATEs was 1.36 (95% CI = 0.86 to 2.17; P = .19). No increase in ATEs was detected in any prespecified subgroup.
%K Antineoplastic Agents
%K Antineoplastic Combined Chemotherapy Protocols
%K Arteries
%K Cisplatin
%K Clinical Trials, Phase II as Topic
%K Clinical Trials, Phase III as Topic
%K Humans
%K Incidence
%K Neoplasms
%K Randomized Controlled Trials as Topic
%K Risk
%K Thromboembolism
%U http://dx.doi.org/10.1093/jnci/djs435
%U http://www.ncbi.nlm.nih.gov/pubmed/23093559
%P 1837-1840

PT Journal
AU Proverbs-Singh, T
   Chiu, SK
   Liu, Z
   Seng, S
   Sonpavde, G
   Choueiri, TK
   Tsao, C
   Yu, M
   Hahn, NM
   Oh, WK
   Galsky, MD
TI Arterial thromboembolism in cancer patients treated with cisplatin: a systematic review and meta-analysis.
SO Journal of the National Cancer Institute
JI J. Natl. Cancer Inst.
PD Dec
PY 2012
BP 1837
EP 1840
VL 104
IS 23
DI 10.1093/jnci/djs435
LA eng
DE Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arteries; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Humans; Incidence; Neoplasms; Randomized Controlled Trials as Topic; Risk; Thromboembolism
AB Cisplatin has been associated with an increased risk of arterial thromboembolic events (ATEs). However, because this association is mostly based on case reports and retrospective studies, we conducted a systemic review and meta-analysis of randomized controlled trials evaluating the incidence and risk of ATEs associated with cisplatin. Eligible studies included prospective randomized phase II and III trials evaluating cisplatin-based vs non-cisplatin-based chemotherapy in patients with solid tumors, which were identified from PubMed articles published between 1990 and 2010. Incidence rates, relative risks (RRs), and 95% confidence intervals (CIs) were calculated using a random effects model. A total of 8216 patients from 38 trials were included. Among patients treated with cisplatin-based chemotherapy, the summary incidence of ATEs was 0.67% (95% CI = 0.40% to 0.95%), and the RR of ATEs was 1.36 (95% CI = 0.86 to 2.17; P = .19). No increase in ATEs was detected in any prespecified subgroup.
ER

PMID- 23093559
OWN - NLM
STAT- MEDLINE
DA  - 20121205
DCOM- 20130204
LR  - 20131121
IS  - 1460-2105 (Electronic)
IS  - 0027-8874 (Linking)
VI  - 104
IP  - 23
DP  - 2012 Dec 5
TI  - Arterial thromboembolism in cancer patients treated with cisplatin: a systematic 
      review and meta-analysis.
PG  - 1837-40
LID - 10.1093/jnci/djs435 [doi]
AB  - Cisplatin has been associated with an increased risk of arterial thromboembolic
      events (ATEs). However, because this association is mostly based on case reports 
      and retrospective studies, we conducted a systemic review and meta-analysis of
      randomized controlled trials evaluating the incidence and risk of ATEs associated
      with cisplatin. Eligible studies included prospective randomized phase II and III
      trials evaluating cisplatin-based vs non-cisplatin-based chemotherapy in patients
      with solid tumors, which were identified from PubMed articles published between
      1990 and 2010. Incidence rates, relative risks (RRs), and 95% confidence
      intervals (CIs) were calculated using a random effects model. A total of 8216
      patients from 38 trials were included. Among patients treated with
      cisplatin-based chemotherapy, the summary incidence of ATEs was 0.67% (95% CI =
      0.40% to 0.95%), and the RR of ATEs was 1.36 (95% CI = 0.86 to 2.17; P = .19). No
      increase in ATEs was detected in any prespecified subgroup.
FAU - Proverbs-Singh, Tracy
AU  - Proverbs-Singh T
AD  - Division of Hematology/Oncology, Tisch Cancer Institute at Mount Sinai Medical
      Center, Mount Sinai School of Medicine, 1 Gustave L Levy Pl, New York, NY 10029, 
      USA.
FAU - Chiu, Sophia K
AU  - Chiu SK
FAU - Liu, Ziyue
AU  - Liu Z
FAU - Seng, Sonia
AU  - Seng S
FAU - Sonpavde, Guru
AU  - Sonpavde G
FAU - Choueiri, Toni K
AU  - Choueiri TK
FAU - Tsao, Che-Kai
AU  - Tsao CK
FAU - Yu, Menggang
AU  - Yu M
FAU - Hahn, Noah M
AU  - Hahn NM
FAU - Oh, William K
AU  - Oh WK
FAU - Galsky, Matthew D
AU  - Galsky MD
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20121023
PL  - United States
TA  - J Natl Cancer Inst
JT  - Journal of the National Cancer Institute
JID - 7503089
RN  - 0 (Antineoplastic Agents)
RN  - Q20Q21Q62J (Cisplatin)
SB  - IM
MH  - Antineoplastic Agents/administration & dosage/*adverse effects
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects
MH  - Arteries
MH  - Cisplatin/administration & dosage/*adverse effects
MH  - Clinical Trials, Phase II as Topic
MH  - Clinical Trials, Phase III as Topic
MH  - Humans
MH  - Incidence
MH  - Neoplasms/*drug therapy
MH  - Randomized Controlled Trials as Topic
MH  - Risk
MH  - Thromboembolism/*chemically induced/*epidemiology
EDAT- 2012/10/25 06:00
MHDA- 2013/02/05 06:00
CRDT- 2012/10/25 06:00
PHST- 2012/10/23 [aheadofprint]
AID - djs435 [pii]
AID - 10.1093/jnci/djs435 [doi]
PST - ppublish
SO  - J Natl Cancer Inst. 2012 Dec 5;104(23):1837-40. doi: 10.1093/jnci/djs435. Epub
      2012 Oct 23.
TY  - JOUR
AU  - Proverbs-Singh, Tracy
AU  - Chiu, Sophia K.
AU  - Liu, Ziyue
AU  - Seng, Sonia
AU  - Sonpavde, Guru
AU  - Choueiri, Toni K.
AU  - Tsao, Che-Kai
AU  - Yu, Menggang
AU  - Hahn, Noah M.
AU  - Oh, William K.
AU  - Galsky, Matthew D.
PY  - 2012/Dec/05
TI  - Arterial thromboembolism in cancer patients treated with cisplatin: a systematic review and meta-analysis.
T2  - J. Natl. Cancer Inst.
JO  - Journal of the National Cancer Institute
SP  - 1837
EP  - 1840
VL  - 104
IS  - 23
KW  - Antineoplastic Agents
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Arteries
KW  - Cisplatin
KW  - Clinical Trials, Phase II as Topic
KW  - Clinical Trials, Phase III as Topic
KW  - Humans
KW  - Incidence
KW  - Neoplasms
KW  - Randomized Controlled Trials as Topic
KW  - Risk
KW  - Thromboembolism
N2  - Cisplatin has been associated with an increased risk of arterial thromboembolic events (ATEs). However, because this association is mostly based on case reports and retrospective studies, we conducted a systemic review and meta-analysis of randomized controlled trials evaluating the incidence and risk of ATEs associated with cisplatin. Eligible studies included prospective randomized phase II and III trials evaluating cisplatin-based vs non-cisplatin-based chemotherapy in patients with solid tumors, which were identified from PubMed articles published between 1990 and 2010. Incidence rates, relative risks (RRs), and 95% confidence intervals (CIs) were calculated using a random effects model. A total of 8216 patients from 38 trials were included. Among patients treated with cisplatin-based chemotherapy, the summary incidence of ATEs was 0.67% (95% CI = 0.40% to 0.95%), and the RR of ATEs was 1.36 (95% CI = 0.86 to 2.17; P = .19). No increase in ATEs was detected in any prespecified subgroup.
SN  - 1460-2105
UR  - http://dx.doi.org/10.1093/jnci/djs435
UR  - http://www.ncbi.nlm.nih.gov/pubmed/23093559
ID  - Proverbs-Singh2012
ER  - 
<?xml version="1.0" encoding="UTF-8"?>
<b:Sources SelectedStyle="" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography"  xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" >
<b:Source>
<b:Tag>Proverbs-Singh2012</b:Tag>
<b:SourceType>ArticleInAPeriodical</b:SourceType>
<b:Year>2012</b:Year>
<b:Month>Dec</b:Month>
<b:Day>5</b:Day>
<b:PeriodicalName>Journal of the National Cancer Institute</b:PeriodicalName>
<b:Volume>104</b:Volume>
<b:Issue>23</b:Issue>
<b:Pages>1837-1840</b:Pages>
<b:Author>
<b:Author><b:NameList>
<b:Person><b:Last>Proverbs-Singh</b:Last><b:First>Tracy</b:First></b:Person>
<b:Person><b:Last>Chiu</b:Last><b:First>Sophia</b:First><b:Middle>K</b:Middle></b:Person>
<b:Person><b:Last>Liu</b:Last><b:First>Ziyue</b:First></b:Person>
<b:Person><b:Last>Seng</b:Last><b:First>Sonia</b:First></b:Person>
<b:Person><b:Last>Sonpavde</b:Last><b:First>Guru</b:First></b:Person>
<b:Person><b:Last>Choueiri</b:Last><b:First>Toni</b:First><b:Middle>K</b:Middle></b:Person>
<b:Person><b:Last>Tsao</b:Last><b:First>Che-Kai</b:First></b:Person>
<b:Person><b:Last>Yu</b:Last><b:First>Menggang</b:First></b:Person>
<b:Person><b:Last>Hahn</b:Last><b:First>Noah</b:First><b:Middle>M</b:Middle></b:Person>
<b:Person><b:Last>Oh</b:Last><b:First>William</b:First><b:Middle>K</b:Middle></b:Person>
<b:Person><b:Last>Galsky</b:Last><b:First>Matthew</b:First><b:Middle>D</b:Middle></b:Person>
</b:NameList></b:Author>
</b:Author>
<b:Title>Arterial thromboembolism in cancer patients treated with cisplatin: a systematic review and meta-analysis.</b:Title>
 <b:ShortTitle>J. Natl. Cancer Inst.</b:ShortTitle>
<b:Comments>Cisplatin has been associated with an increased risk of arterial thromboembolic events (ATEs). However, because this association is mostly based on case reports and retrospective studies, we conducted a systemic review and meta-analysis of randomized controlled trials evaluating the incidence and risk of ATEs associated with cisplatin. Eligible studies included prospective randomized phase II and III trials evaluating cisplatin-based vs non-cisplatin-based chemotherapy in patients with solid tumors, which were identified from PubMed articles published between 1990 and 2010. Incidence rates, relative risks (RRs), and 95% confidence intervals (CIs) were calculated using a random effects model. A total of 8216 patients from 38 trials were included. Among patients treated with cisplatin-based chemotherapy, the summary incidence of ATEs was 0.67% (95% CI = 0.40% to 0.95%), and the RR of ATEs was 1.36 (95% CI = 0.86 to 2.17; P = .19). No increase in ATEs was detected in any prespecified subgroup.</b:Comments>
</b:Source>
</b:Sources>